Brooklyn ImmunoTherapeutics Net Tangible Assets

Brooklyn ImmunoTherapeutics's net tangible assets stands at $920M as of December 2025. That compares with $1.8B in the prior-year period — down 48.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Brooklyn ImmunoTherapeutics reported $920M in net tangible assets versus $1.8B a year earlier — a 48.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.8B in the prior-year period — down 48.7% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Brooklyn ImmunoTherapeutics's net tangible assets evolved across reporting periods, while the comparison chart places BTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Telecommunications, net tangible assets is commonly used to spot outliers. Brooklyn ImmunoTherapeutics's reading of $920M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.